Claims
- 1. A method for preventing, treating or managing cancer in a patient in need thereof, said method comprising administering to said patient a prophylactically or therapeutically effective amount of one or more JNK inhibitors and a prophylactically or therapeutically effective amount of another chemotherapeutic agent.
- 2. The method of claim 1 wherein the chemotherapeutic agent is an apoptosis inducing agent.
- 3. The method of claim 1 wherein the chemotherapeutic agent is an anti-angiogenic agent.
- 4. The method of claim 1 wherein the chemotherapeutic agent is a cytotoxic agent.
- 5. The method of claim 1 wherein the chemotherapeutic agent is an antimetabolite.
- 6. The method of claim 1 wherein the chemotherapeutic agent is an antimitotic agent.
- 7. The method of claim 1 wherein the chemotherapeutic agent is a modulator of TNF-alpha.
- 8. The method of claim 1 wherein the chemotherapeutic agent is a tubulin stabilizing agent.
- 9. The method of claim 1 wherein the chemotherapeutic agent is a microtubule formation inhibiting agent.
- 10. The method of claim 1 wherein the chemotherapeutic agent is a topoisomerase inhibitor.
- 11. The method of claim 1 wherein the chemotherapeutic agent is an anti-metastatic agent.
- 12. The method of claim 1 wherein the chemotherapeutic agent is a DNA interactive agent.
- 13. The method of claim 12 wherein the DNA interactive agent is a DNA alkylating agent.
- 14. The method of claim 12 wherein the DNA interactive agent is a DNA intercalating agent.
- 15. The method of claim 1 wherein the patient is a human.
- 16. The method of claim 1 wherein the chemotherapeutic agent is paclitaxel, irinotecan, cyclophosphamide, 5-fluorouracil, cisplatinum, carboplatin, methotrexate, doxorubicin, thalidomide, cetuximab, CC-4047 and CC-501.
- 17. A method for increasing the efficacy of cancer chemotherapeutic agents which comprises administering to a patient in need thereof a therapeutically effective amount one or more JNK inhibitors.
- 18. The method of claim 17 wherein the patient has undergone cancer treatment.
- 19. The method of claim 17 wherein the patient is undergoing cancer treatment.
- 20. The method of claim 1 or 17 wherein the cancer is resistant to cancer treatment.
- 21. The method of claim 1 or 17, wherein the JNK inhibitor is a small organic molecule.
- 22. The method of claim 1, wherein the JNK inhibitor is:
- 23. The method of claim 1, wherein the JNK inhibitor is:
- 24. The method of claim 1, wherein the JNK inhibitor is:
- 25. A method of reducing or preventing one or more adverse effects or toxicities associated with the administration of a chemotherapeutic agent or radiation therapy comprising administering to a patient in need thereof a therapeutically effective amount of one or more JNK inhibitors.
- 26. A method of reducing the dosage or frequency of administration of a chemotherapeutic agent or radiation therapy comprising administering a therapeutically effective amount one or more JNK inhibitors to a patient in need thereof.
- 27. A method of increasing the anti-tumor activity of a chemotherapeutic agent radiation therapy comprising administering a therapeutically effective amount one or more JNK inhibitors to a patient in need thereof.
- 28. A method of increasing the selective cytotoxicity of a chemotherapeutic agent comprising the administration of a therapeutically effective amount one or more JNK inhibitors to a patient in need thereof.
- 29. The method of claim 26, wherein the chemotherapeutic agent is paclitaxel.
- 30. The method of claim 26, wherein the chemotherapeutic agent is cyclophosphamide.
- 31. The method of claim 1, wherein said cancer is the of head, neck, eye, mouth, throat, esophagus, chest, bone, lung, colon, rectum, stomach, prostate, breast, ovaries, testicles or other reproductive organs, skin, thyroid, blood, lymph nodes, kidney, liver, pancreas, brain or central nervous system.
- 32. The method of claims 17, 24, 25, 26 or 27, wherein said patient has cancer of the head, neck, eye, mouth, throat, esophagus, chest, bone, lung, colon, rectum, stomach, prostate, breast, ovaries, testicles or other reproductive organs, skin, thyroid, blood, lymph nodes, kidney, liver, pancreas, brain or central nervous system.
- 33. A method of treating cancer in a refractory patient which comprises administering to said patient a therapeutically effective amount of one or more JNK inhibitors.
Parent Case Info
[0001] This application claims the benefit of U.S. provisional application 60/362,705, filed Mar. 8, 2002, the contents of which are incorporated by reference herein in their entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60362705 |
Mar 2002 |
US |